Darwin and Chiroscience tie the knot
This article was originally published in Clinica
Executive Summary
Darwin Molecular, the US epitome of high-tech genomics companies, has fallen prey to UK drug maker Chiroscience. In a move that surprised the world of biotechnology, Chiroscience last week revealed a $120-million stock swap takeover of the Seattle-based company.